USE IN PREGNANCY
When used in pregnancy during the second and third trimesters, ACE inhibitors can cause injury and even death to the developing fetus. When pregnancy is detected, ACCUPRIL should be discontinued as soon as possible. See WARNINGS, Fetal/Neonatal Morbidity and Mortality.
|
| |
ACCUPRIL SUMMARY
Accupril®
(Quinapril Hydrochloride Tablets)
ACCUPRIL® (quinapril hydrochloride) is the hydrochloride salt of quinapril, the ethyl ester of a non-sulfhydryl, angiotensin-converting enzyme (ACE) inhibitor, quinaprilat.
ACCUPRIL is indicated for the treatment of hypertension. It may be used alone or in combination with thiazide diuretics.
ACCUPRIL is indicated in the management of heart failure as adjunctive therapy when added to conventional therapy including diuretics and/or digitalis.
In using ACCUPRIL, consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease. Available data are insufficient to show that ACCUPRIL does not have a similar risk (see WARNINGS).
Angioedema in black patients: Black patients receiving ACE inhibitor monotherapy have been reported to have a higher incidence of angioedema compared to non-blacks. It should also be noted that in controlled clinical trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks.
|
NEWS HIGHLIGHTS
Published Studies Related to Accupril (Quinapril)
Lack of efficacy of quinapril on vascular damage in limited cutaneous systemic sclerosis. [2008.06]
Gliddon et al... There were no detectable differences between patients treated with quinapril and those receiving placebo; however, although no severe adverse effects were observed, patients taking quinapril experienced significantly more adverse effects.
Prevention of vascular damage in scleroderma and autoimmune Raynaud's phenomenon: a multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinapril. [2007.11]
OBJECTIVE: To evaluate the efficacy and tolerability of prolonged administration of quinapril, a long-acting angiotensin-converting enzyme inhibitor, in the management of the peripheral vascular manifestations of limited cutaneous systemic sclerosis (lcSSc) and in the prevention of the progression of visceral organ involvement in the disease... CONCLUSION: Administration of quinapril for up to 3 years had no demonstrable effects on the occurrence of upper limb digital ulcers or on other vascular manifestations of lcSSc in this patient population.
The role of quinapril in the presence of a weight loss regimen: endothelial function and markers of obesity in patients with the metabolic syndrome. [2007.09]
Forty-four patients with the metabolic syndrome were placed on a reduced-calorie and reduced-fat regimen to lose weight throughout a 56-week period. The patients were treated in a crossover fashion with placebo and the angiotensin-converting enzyme inhibitor quinapril for 24 weeks each... These results are potentiated with quinapril and are independent of changes in metabolic parameters.
Amlodipine added to quinapril vs quinapril alone for the treatment of hypertension in diabetes: the Amlodipine in Diabetes (ANDI) trial. [2007.02]
This randomized, comparative, parallel-group trial investigated strategies of blood pressure (BP)-lowering in patients with diabetes and hypertension. Patients not reaching goal BP (<130/80 mm Hg) after 4-week open-label treatment with quinapril 20 mg/d (n=374) received 40 mg/d quinapril (n=167) or 20 mg/d quinapril plus amlodipine besylate (5 mg/d; n=162) for 6 weeks...
Quinapril for treatment of hypertension in Turkey: dose titration and diuretic combination treatment strategies. [2007]
BACKGROUND and objective: Recently the PatenT (Prevalence, awareness, treatment and control of hypertension in Turkey) study showed that while the prevalence of hypertension in Turkey is high, effective control of BP is infrequently achieved. This study investigated the efficacy and safety of quinapril (as monotherapy or in combination with hydrochlorothiazide [HCTZ]) for achieving BP control (target <140/90 mm Hg) in Turkish subjects with mild to moderate hypertension... CONCLUSION: Quinapril was an effective and safe treatment for achieving and maintaining recommended BP targets in this sample population. These findings will provide clinicians in Turkey with valuable data on the use of quinapril for effective control and management of hypertension.
Clinical Trials Related to Accupril (Quinapril)
A Study to Evaluate the Efficacy and Safety of Quinapril or Quinapril Plus Hydrochlorothiazide in Patients With Mild to Moderate Hypertension [Completed]
The purpose of this study is to determine the response rate for the therapeutic goal
(diastolic blood pressure (BP) less than 90 mmHg and systolic BP less than 140 mmHg) at Week
6 for quinapril 20 mg and at Week 12 for quinapril 20 mg, quinapril 40 mg, and quinapril 20
mg plus hydrochlorothiazide 12. 5 mg; and to determine the mean decrease in diastolic and
systolic BP measurements and the change in heart rate at Week 6 and Week 12 compared with
baseline.
Food Study of Quinapril Hydrochloride Tablets 40 mg and Accupril® Tablets 40 mg [Completed]
The objective of this study was to investigate the bioequivalence of Mylan quinapril
hydrochloride 40 mg tablets compared to Parke-Davis Accupril® 40 mg tablets following a
single, oral 40 mg (1 x 40 mg) dose under fed conditions.
Fasting Study of Quinapril Hydrochloride Tablets 40 mg and Accupril® Tablets 40 mg [Completed]
The objective of this study was to investigate the bioequivalence of Mylan quinapril
hydrochloride 40 mg tablets compared to Parke-Davis Accupril® 40 mg tablets following a
single, oral 40 mg (1 x 40 mg) dose under fasting conditions.
High-Dose Quinapril Versus Low-Dose Quinapril Plus Amlodipine in the Treatment of High-Risk Hypertensive Patients [Terminated]
The purpose of this study is to compare the impact of two blood pressure lowering treatments
(high dose quinapril versus low dose quinapril plus amlodipine) on variations in heart rate
over 24 hours.
Comparison of Quinapril 40 mg With Alpha Lipoic Acid or Placebo on Patients With Diabetes Mellitus (DM) and Hypertension (HTN) [Recruiting]
We will evaluate the combination of quinapril and alpha lipoic acid in patients with diabetes
mellitus and hypertension. We will determine whether the combination of quinapril and lipoic
acid as compared to quinapril and placebo provides benefit on systemic blood pressure and
proteinuria.
|
PATIENT REVIEWS / RATINGS / COMMENTSBased on a total of 1 ratings/reviews, Accupril has an overall score of 9. The effectiveness score is 8 and the side effect score is 10. The scores are on ten point scale: 10 - best, 1 - worst.
| | Accupril review by 57 year old female patient | | | Rating |
| Overall rating: | |   |
| Effectiveness: | | Considerably Effective |
| Side effects: | | No Side Effects | | |
Treatment Info |
| Condition / reason: | | hypertension |
| Dosage & duration: | | 40 mg taken once daily for the period of 7 years |
| Other conditions: | | hypertension |
| Other drugs taken: | | hyzaar | | |
Reported Results |
| Benefits: | | lower blood pressure in combination with Hyzaar |
| Side effects: | | None I am aware of. |
| Comments: | | Taken once daily in combination with Hyzaar. My condition apparently responded best to the two medications. However, my doctor said that recent discussions have gone against taking the two classes of antihypertensives so I am now on an increased dose of Hyzaar. |
|
|
|
Page last updated: 2008-06-22
|
